運動失調症の世界市場レポート 2025年

運動失調症の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.9%で570億1,000万米ドルに成長します。予測期間の成長は、運動失調症の医薬品開発の加速、希少疾患研究への投資の増加、プレシジョン・メディシン・アプローチの採用、患者アドボカシーの重点化、運動失調症の遺伝的基盤に対する理解の深まりなどに起因しています。予測期間における主な動向としては、運動失調症管理におけるデジタルヘルスソリューションの統合、運動失調症治療のための遺伝子治療の開発、共同研究イニシアチブの増加、患者中心のケアモデルの重視、運動失調症診察のための遠隔医療の採用などが挙げられます。

アルコール消費量の増加が運動失調症市場の成長を促進すると予想されます。アルコール消費とは、エタノールを含む飲料の摂取を指し、通常は経口摂取されます。小脳変性症は、後天性毒性運動失調症の一般的な形態であり、慢性的なアルコールの誤用に起因します。アルコール依存症の患者は、しばしば下肢の姿勢振戦や歩行運動失調症を経験します。例えば、2024年8月に英国政府機関のGOV.UKが発表したところによると、2024年5月から7月までのワインおよびその他の発酵製品からのアルコール税の暫定的な受取総額は11億5,400万英ポンドに達し、前年同期に比べ3,200万英ポンド（2.9％）増加しました。したがって、アルコール消費量の増加が運動失調症市場の成長に寄与しています。

ヘルスケア支出の増加は、今後数年間の運動失調症市場の拡大を促進すると予測されます。ヘルスケア支出の増加には、運動失調症に関連する疾患を対象とした革新的な治療法や治療法の高度な研究開発、利用可能性に向けた資源の配分が含まれます。ヘルスケア支出の増加に伴い、運動失調症の理解と管理を強化するための協調的な取り組みが行われています。例えば、メディケア＆メディケイドサービスセンターが2022年3月に発表した2021-2030年国民医療費（NHE）報告書による予測では、国民医療費は年平均5.1％増加し、2030年には約6兆8,000億米ドルにまで大幅に増加すると予測されています。その結果、ヘルスケア支出の増加傾向は、運動失調症市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の運動失調症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の運動失調症市場：成長率分析
• 世界の運動失調症市場の実績：規模と成長, 2019-2024
• 世界の運動失調症市場の予測：規模と成長, 2024-2029, 2034F
• 世界の運動失調症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の運動失調症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フリードライヒの運動失調症
• 毛細血管拡張性運動失調症
• エピソード性運動失調症
• その他のタイプ
• 世界の運動失調症市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療
• 診断
• 世界の運動失調症市場：剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 固体
• 液体
• その他の剤形
• 世界の運動失調症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の運動失調症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ヘルスケア
• その他のエンドユーザー
• 世界の運動失調症市場、タイプ別サブセグメンテーション：フリードライヒ運動失調症、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝カウンセリングと検査
• 対症療法
• 世界の運動失調症市場、タイプ別サブセグメンテーション：毛細血管拡張性運動失調症、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法
• 支持療法
• 世界の運動失調症市場、タイプ別サブセグメンテーション：発作性運動失調症、実績と予測, 2019-2024, 2024-2029F, 2034F
• 発作薬
• 長期経営戦略
• 世界の運動失調症市場、タイプ別サブセグメンテーション：その他のタイプ、実績と予測, 2019-2024, 2024-2029F, 2034F
• 脊髄小脳失調症（SCA）
• 運動失調症ビタミン欠乏症または毒素別

第7章 地域別・国別分析

• 世界の運動失調症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の運動失調症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 運動失調症市場：競合情勢
• 運動失調症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • CRISPR Therapeutics AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bio-Techne Corporation
• Cellectis SA
• Eli Lilly & Company
• GlaxoSmithKline Plc
• Larimar Therapeutics Inc.
• Capsida Biotherapeutics Inc.
• Intellia Therapeutics Inc.
• Bluebird bio Inc.
• AAVLife SAS
• Editas Medicine Inc.
• Healx
• Acorda Therapeutics Inc.
• H. Lundbeck A/S
• Reata Pharmaceuticals Inc.
• Retrotope Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 運動失調症市場2029：新たな機会を提供する国
• 運動失調症市場2029：新たな機会を提供するセグメント
• 運動失調症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ataxia is a neurological disorder characterized by irregular movements and challenges with balance, stemming from a lack of muscular control and coordination. This condition affects various body regions, including limbs, speech, and eye movements.

The primary types of ataxias encompass Friedreich's ataxia, ataxia-telangiectasia, episodic ataxia, and others. Friedreich's ataxia is a rare genetic disorder that disrupts movement and progressively damages the nervous system. Treatment options and diagnostic methods are available for managing this condition. These treatments come in different forms, including solids and liquids, and can be administered through various routes such as oral and parenteral. The end-users for these treatments include hospitals, clinics, home healthcare, and others.

The ataxia market research report is one of a series of new reports from The Business Research Company that provides ataxia market statistics, including ataxia industry global market size, regional shares, competitors with a ataxia market share, detailed ataxia market segments, market trends and opportunities, and any further data you may need to thrive in the ataxia industry. This ataxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ataxia market size has grown strongly in recent years. It will grow from $37.24 billion in 2024 to $40.59 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to limited treatment options, advances in neurological research, growing awareness of rare diseases, evolution of diagnostic technologies, increased focus on genetic factors

The ataxia market size is expected to see strong growth in the next few years. It will grow to $57.01 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to accelerated drug development for ataxia, rising investments in rare disease research, adoption of precision medicine approaches, increased focus on patient advocacy, growing understanding of the genetic basis of ataxia. Major trends in the forecast period include integration of digital health solutions in ataxia management, development of gene therapies for ataxia treatment, rise in collaborative research initiatives, emphasis on patient-centric care models, adoption of telemedicine for ataxia consultations.

The increase in alcohol consumption is anticipated to drive the growth of the ataxia market. Alcohol consumption refers to the intake of beverages containing ethanol, typically consumed orally. Cerebellar degeneration, a common form of acquired toxic ataxia, results from chronic alcohol misuse. Patients with alcoholism often experience lower limb postural tremors and gait ataxia. For instance, in August 2024, GOV.UK, a UK government department, reported that the provisional total for Alcohol Duty receipts from wine and other fermented products between May and July 2024 reached £1,154 million, marking an increase of £32 million (2.9%) compared to the same period the previous year. Therefore, the rise in alcohol consumption is contributing to the growth of the ataxia market.

The upsurge in healthcare expenditure is anticipated to drive the expansion of the ataxia market in the coming years. Elevated healthcare spending encompasses the allocation of resources toward advanced research, development, and accessibility of innovative treatments and therapies targeting ataxia-related conditions. As healthcare expenditures rise, there's a concerted effort to enhance the understanding and management of ataxia. For instance, projections from the 2021-2030 National Health Expenditure (NHE) report, released by the Centers for Medicare & Medicaid Services in March 2022, indicated an average annual increase of 5.1% in national health spending, foreseeing a substantial rise to approximately $6.8 trillion by 2030. Consequently, the upward trajectory in healthcare expenditure acts as a driving force behind the growth observed within the ataxia market.

Innovative product development is a prominent trend gaining momentum within the ataxia market. Leading companies within this domain are committed to introducing novel products or drugs to fortify their market presence. A case in point is the announcement made by Reata Pharmaceuticals in February 2023, unveiling the FDA approval of SKYCLARYS (omavaloxolone). This groundbreaking medication stands as the inaugural drug indicated specifically for individuals with Friedreich's ataxia, encompassing adults and adolescents aged 16 and above. Notably, treatment with SKYCLARYS demonstrated a statistically significant reduction in mFARS (modified Friedreich's Ataxia Rating Scale) scores at Week 48, evidencing diminished impairment compared to a placebo. Friedreich's ataxia, an exceedingly rare inherited neurological disorder, is commonly diagnosed during adolescence.

Major companies in the ataxia market are concentrating on developing innovative solutions, such as drug treatments for ataxia, to improve symptom management and enhance patient outcomes. Ataxia drug treatment consists of medications aimed at managing and alleviating the symptoms of ataxia, a neurological condition marked by impaired coordination, balance, and speech. For instance, in March 2023, Reata Pharmaceuticals, a US-based pharmaceutical company, received FDA approval for SKYCLARYS (omaveloxolone), the first drug specifically indicated for the treatment of Friedreich's ataxia. This milestone follows promising results from the Phase 2 MOXIe trial, where patients treated with SKYCLARYS demonstrated significantly slower neurological decline compared to those receiving a placebo. The drug activates the Nrf2 protein, crucial for mitochondrial health, addressing a central issue in Friedreich's ataxia. This approval not only brings hope to patients and their families but also sets a precedent for future treatments of rare diseases.

In December 2022, Solid Biosciences Inc., a US-based biotech company, successfully completed the acquisition of AavantiBio Inc. for an undisclosed amount. This strategic move allows Solid Biosciences Inc. to gain access to AavantiBio's portfolio of neuromuscular and cardiac programs. Notable assets acquired include the differentiated gene transfer candidate SGT-003 for Duchenne, the gene transfer candidate AVB-202 for Friedreich's ataxia, the gene transfer candidate AVB-401 for BAG3-mediated dilated cardiomyopathy, along with additional assets designed for the treatment of unspecified cardiac diseases. AavantiBio Inc. is recognized as a leading gene therapy company in the United States, specializing in the treatment of Friedreich's ataxia and cardiovascular diseases.

Major companies operating in the ataxia market include Pfizer Inc., Johnson & Johnson Services Inc., Eisai Co. Ltd., Genentech Inc., CRISPR Therapeutics AG, Bio-Techne Corporation, Cellectis SA, Eli Lilly & Company, GlaxoSmithKline Plc, Larimar Therapeutics Inc., Capsida Biotherapeutics Inc., Intellia Therapeutics Inc., Bluebird bio Inc., AAVLife SAS, Editas Medicine Inc., Healx, Acorda Therapeutics Inc., H. Lundbeck A/S, Reata Pharmaceuticals Inc., Retrotope Inc., PTC Therapeutics, Zydus Lifesciences Ltd, Ionis Pharmaceuticals Inc, Blade Therapeutics, IntraBio, Biogen Inc., Novartis AG, Pfizer Inc., Sanofi, Roche Holding Ltd., Teva Pharmaceuticals, H. Lundbeck A/S, CRISPR Therapeutics AG, Acorda Therapeutics Inc.

North America was the largest region in the ataxia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the ataxia market report during the forecast period. The regions covered in the ataxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ataxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ataxia market consists of revenues earned by entities by providing serotonergic therapy, occupational therapy, vestibular rehabilitation, and hyperbaric oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ataxia market also includes sales of adaptive devices including walkers or canes, acetazolamide, and amantadine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ataxia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ataxia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ataxia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ataxia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Friedreich's Ataxia; Ataxia-telangiectasia; Episodic Ataxia; Other Types
• 2) By Product: Treatment; Diagnosis
• 3) By Dosage Form: Solid; Liquids; Other Dosage Forms
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End User: Hospital; Clinics; Home Healthcare; Other End-Users
• Subsegments:
• 1) By Friedreich's Ataxia: Genetic Counseling And Testing; Symptomatic Treatments
• 2) By Ataxia-telangiectasia: Immunotherapy; Supportive Care
• 3) By Episodic Ataxia: Medications For Episodes; Long-term Management Strategies
• 4) By Other Types: Spinocerebellar Ataxias (SCAs); Ataxia Due To Vitamin Deficiencies Or Toxins
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Eisai Co. Ltd.; Genentech Inc.; CRISPR Therapeutics AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ataxia Market Characteristics

3. Ataxia Market Trends And Strategies

4. Ataxia Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Ataxia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ataxia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ataxia Market Growth Rate Analysis
• 5.4. Global Ataxia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ataxia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ataxia Total Addressable Market (TAM)

6. Ataxia Market Segmentation

• 6.1. Global Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Friedreich's Ataxia
• Ataxia-telangiectasia
• Episodic Ataxia
• Other Types
• 6.2. Global Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Treatment
• Diagnosis
• 6.3. Global Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solid
• Liquids
• Other Dosage Forms
• 6.4. Global Ataxia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.5. Global Ataxia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinics
• Home Healthcare
• Other End-Users
• 6.6. Global Ataxia Market, Sub-Segmentation Of Friedreich's Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Counseling And Testing
• Symptomatic Treatments
• 6.7. Global Ataxia Market, Sub-Segmentation Of Ataxia-telangiectasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Supportive Care
• 6.8. Global Ataxia Market, Sub-Segmentation Of Episodic Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications For Episodes
• Long-term Management Strategies
• 6.9. Global Ataxia Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spinocerebellar Ataxias (SCAs)
• Ataxia Due To Vitamin Deficiencies Or Toxins

7. Ataxia Market Regional And Country Analysis

• 7.1. Global Ataxia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ataxia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ataxia Market

• 8.1. Asia-Pacific Ataxia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ataxia Market

• 9.1. China Ataxia Market Overview
• 9.2. China Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ataxia Market

• 10.1. India Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ataxia Market

• 11.1. Japan Ataxia Market Overview
• 11.2. Japan Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ataxia Market

• 12.1. Australia Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ataxia Market

• 13.1. Indonesia Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ataxia Market

• 14.1. South Korea Ataxia Market Overview
• 14.2. South Korea Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ataxia Market

• 15.1. Western Europe Ataxia Market Overview
• 15.2. Western Europe Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ataxia Market

• 16.1. UK Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ataxia Market

• 17.1. Germany Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ataxia Market

• 18.1. France Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ataxia Market

• 19.1. Italy Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ataxia Market

• 20.1. Spain Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ataxia Market

• 21.1. Eastern Europe Ataxia Market Overview
• 21.2. Eastern Europe Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ataxia Market

• 22.1. Russia Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ataxia Market

• 23.1. North America Ataxia Market Overview
• 23.2. North America Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ataxia Market

• 24.1. USA Ataxia Market Overview
• 24.2. USA Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ataxia Market

• 25.1. Canada Ataxia Market Overview
• 25.2. Canada Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ataxia Market

• 26.1. South America Ataxia Market Overview
• 26.2. South America Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ataxia Market

• 27.1. Brazil Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ataxia Market

• 28.1. Middle East Ataxia Market Overview
• 28.2. Middle East Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ataxia Market

• 29.1. Africa Ataxia Market Overview
• 29.2. Africa Ataxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ataxia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ataxia Market Competitive Landscape And Company Profiles

• 30.1. Ataxia Market Competitive Landscape
• 30.2. Ataxia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. CRISPR Therapeutics AG Overview, Products and Services, Strategy and Financial Analysis

31. Ataxia Market Other Major And Innovative Companies

• 31.1. Bio-Techne Corporation
• 31.2. Cellectis SA
• 31.3. Eli Lilly & Company
• 31.4. GlaxoSmithKline Plc
• 31.5. Larimar Therapeutics Inc.
• 31.6. Capsida Biotherapeutics Inc.
• 31.7. Intellia Therapeutics Inc.
• 31.8. Bluebird bio Inc.
• 31.9. AAVLife SAS
• 31.10. Editas Medicine Inc.
• 31.11. Healx
• 31.12. Acorda Therapeutics Inc.
• 31.13. H. Lundbeck A/S
• 31.14. Reata Pharmaceuticals Inc.
• 31.15. Retrotope Inc.

32. Global Ataxia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ataxia Market

34. Recent Developments In The Ataxia Market

35. Ataxia Market High Potential Countries, Segments and Strategies

• 35.1 Ataxia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ataxia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ataxia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer